Methods for treatment of cancer with an anti-tigit antagonist antibody
US-2024424092-A1 · Dec 26, 2024 · US
Single dose oral formulations and methods for treatment of cats with ectoparasiticidal spinosad
US9220719B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9220719-B2 |
| Application number | US-201313944904-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 18, 2013 |
| Priority date | Jul 26, 2012 |
| Publication date | Dec 29, 2015 |
| Grant date | Dec 29, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention provides a single-dose oral formulation of spinosad for the extended control of a C. felis infestation on a cat at a predictable dose of spinosad that is suitable for administration once every 30 days (i.e., one month). The invention also provides methods of using the formulation of spinosad.
First claim
Opening claim text (preview).
The invention claimed is: 1. A single-dose oral formulation for controlling a C. felis infestation on a cat comprising an ectoparasiticidal amount of spinosad, microcrystalline cellulose, hydroxypropylcellulose, colloidal silicon (anhydrous), croscarmellose sodium, and magnesium stearate, and optionally an artificial flavor, wherein the formulation is suitable for oral administration once every 30 days at a dose of at least about 50 mg of spinosad per kg of body weight of the cat…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
- A61K31/7048Primary
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9220719B2 cover?
- This invention provides a single-dose oral formulation of spinosad for the extended control of a C. felis infestation on a cat at a predictable dose of spinosad that is suitable for administration once every 30 days (i.e., one month). The invention also provides methods of using the formulation of spinosad.
- Who is the assignee on this patent?
- Lilly Co Eli
- What technology area does this patent fall under?
- Primary CPC classification A61K31/7048. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 29 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).